SCHEMBL1516640

SCHEMBL1516640

Fc1cc(OBOc2ccc(OCc3ccccc3)c(F)c2)ccc1OCc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
S1PR5 Q9H228 1/20 0.45
FFAR1 O14842 5/20 0.45
PPARD Q03181 4/20 0.45
SCN9A Q15858 1/20 0.44
ALOX5 P09917 1/20 0.44
MRGPRX4 Q96LA9 4/20 0.43
KDM1A O60341 2/20 0.43
LMNA P02545 1/20 0.42
CYP1A2 P05177 1/20 0.42
PTGS1 P23219 1/20 0.42
SLC6A2 P23975 1/20 0.42
CYP2C19 P33261 1/20 0.42
PTGS2 P35354 1/20 0.42
SLC6A3 Q01959 1/20 0.42
HIF1A Q16665 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
MAOB P27338 1/20 0.42
ERN1 O75460 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16034065 0.88 ALOX5 (0.44) ALOX5MRGPRX4KDM1ALMNACYP1A2
SCHEMBL27882779 0.83 MAOB (0.58) FFAR1PPARDMAOBERN1
SCHEMBL1128493 0.81 FFAR1 (0.59) FFAR1PPARDALOX5MRGPRX4KDM1A
SCHEMBL4986557 0.81 NPC1 (0.52) ALOX5MRGPRX4CYP1A2CYP2C19
SCHEMBL906203 0.80 NPC1 (0.53) LMNACYP1A2MAOB
SCHEMBL7371207 0.79 FFAR1 (0.46) S1PR5FFAR1PPARDSCN9AALOX5
SCHEMBL30844043 0.79 FFAR1 (0.48) S1PR5FFAR1PPARDSCN9AMRGPRX4
SCHEMBL4770223 0.79 LIPE (0.46) S1PR5FFAR1PPARDSCN9AALOX5
SCHEMBL412514 0.78 MRGPRX4 (0.53) S1PR5MRGPRX4KDM1ALMNA
SCHEMBL30719648 0.78 MRGPRX4 (0.53) S1PR5MRGPRX4KDM1ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112279768-B Polymerizable compounds and their use in liquid crystal displays 默克专利股份有限公司 2024-01-30 CN disclosed
EP-3124465-B1 POLYMERISABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS MERCK PATENT GMBH (DE) 2022-09-28 EP disclosed
US-11414599-B2 Polymerizable compounds and the use thereof in liquid-crystal displays MERCK PATENT GMBH (DE) 2022-08-16 US disclosed
US-11225606-B2 Polymerizable compounds and the use thereof in liquid-crystal displays MERCK PATENT GMBH (DE) 2022-01-18 US disclosed
US-20200248078-A1 POLYMERIZABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS MERCK PATENT GMBH (DE) 2020-08-06 US disclosed
EP-3121247-B1 POLYMERISABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS MERCK PATENT GMBH (DE) 2019-10-02 EP disclosed
US-20190256777-A1 POLYMERIZABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS MERCK PATENT GMBH (DE) 2019-08-22 US disclosed
US-10344215-B2 Polymerizable compounds and the use thereof in liquid-crystal displays MERCK PATENT GMBH (DE) 2019-07-09 US disclosed
US-9938229-B2 Polymerisable compounds and the use thereof in liquid-crystal displays MERCK PATENT GMBH (DE) 2018-04-10 US disclosed
EP-3124465-A1 POLYMERISABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS Merck Patent GmbH (DE) 2017-02-01 EP disclosed
US-7361764-B2 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS, INC. (US) 2008-04-22 US disclosed
US-7361763-B2 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS, INC. (US) 2008-04-22 US disclosed
WO-2007106236-A2 PYRROLO-PYRIDINE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2007-09-20 WO disclosed
EP-1781654-A1 PYRROLO-PYRIDINE KINASE MODULATORS SGX Pharmaceuticals, Inc. (US) 2007-05-09 EP disclosed
US-20070072901-A1 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 GLAXO GROUP LIMITED (GB) 2007-03-29 US disclosed
US-20070043068-A1 to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine SGX PHARMACEUTICALS, INC. (US) 2007-02-22 US disclosed
EP-1689718-A1 1-AMINO-ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INAPPROPRIATE ALK5 ACTIVITY GLAXO GROUP LIMITED (GB) 2006-08-16 EP disclosed
US-20060030583-A1 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS, INC. (US) 2006-02-09 US disclosed
WO-2006015123-A1 PYRROLO-PYRIDINE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2006-02-09 WO disclosed
WO-2005049577-A1 1-AMINO-ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INAPPROPRIATE ALK5 GLAXO GROUP LIMITED (GB) 2005-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11225606-B2 Polymerizable compounds and the use thereof in liquid-crystal displays VCL, PLEC, EML4 S1PR5 2994/4885FFAR1 3780/4885PPARD 3186/4885
US-10344215-B2 Polymerizable compounds and the use thereof in liquid-crystal displays VCL, PLEC, EML4 S1PR5 2994/4885FFAR1 3780/4885PPARD 3186/4885
US-11414599-B2 Polymerizable compounds and the use thereof in liquid-crystal displays VCL, PLEC, EML4 S1PR5 2994/4885FFAR1 3780/4885PPARD 3186/4885
US-20190256777-A1 POLYMERIZABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS VCL, PLEC, EML4 S1PR5 2994/4885FFAR1 3780/4885PPARD 3186/4885
US-20060030583-A1 Pyrrolo-pyridine kinase modulators MAP3K20, MAP4K2, MAP3K19 S1PR5 1799/4885FFAR1 3409/4885PPARD 1132/4885
US-20200248078-A1 POLYMERIZABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS VCL, PLEC, EML4 S1PR5 2994/4885FFAR1 3780/4885PPARD 3186/4885
US-20070072901-A1 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 ALK, NPR3, CBR3 S1PR5 391/4885FFAR1 701/4885PPARD 3514/4885
US-20070043068-A1 to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine MAP3K20, MAP4K2, MAP3K6 S1PR5 1136/4885FFAR1 2434/4885PPARD 1810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.